These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26699830)

  • 1. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
    Seidel C; Oechsle K; Lorch A; Dieing A; Hentrich M; Hornig M; Grünwald V; Cathomas R; Meiler J; de Wit M; Bokemeyer C
    Urol Oncol; 2016 Apr; 34(4):167.e21-8. PubMed ID: 26699830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
    Bokemeyer C; Oechsle K; Honecker F; Mayer F; Hartmann JT; Waller CF; Böhlke I; Kollmannsberger C;
    Ann Oncol; 2008 Mar; 19(3):448-53. PubMed ID: 18006893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
    Oechsle K; Kollmannsberger C; Honecker F; Mayer F; Waller CF; Hartmann JT; Boehlke I; Bokemeyer C;
    Eur Urol; 2011 Oct; 60(4):850-5. PubMed ID: 21704446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
    Kollmannsberger C; Beyer J; Liersch R; Schoeffski P; Metzner B; Hartmann JT; Rick O; Stengele K; Hohloch K; Spott C; Kanz L; Bokemeyer C
    J Clin Oncol; 2004 Jan; 22(1):108-14. PubMed ID: 14701772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer.
    Uchida M; Kawai K; Kimura T; Ichioka D; Takaoka E; Suetomi T; Miyazaki J; Nishiyama H
    Int J Clin Oncol; 2014 Dec; 19(6):1112-7. PubMed ID: 24647526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience.
    De Giorgi U; Rosti G; Papiani G; Aieta M; Fochessati F; Paoluzzi L; Valduga F; Marangolo M
    Am J Clin Oncol; 2004 Oct; 27(5):457-60. PubMed ID: 15596910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
    Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
    J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum-refractory germ cell tumors: an update on current treatment options and developments.
    Oing C; Alsdorf WH; von Amsberg G; Oechsle K; Bokemeyer C
    World J Urol; 2017 Aug; 35(8):1167-1175. PubMed ID: 27449639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
    Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.
    Theodore C; Chevreau C; Yataqhene Y; Fizazi K; Delord JP; Lotz JP; Geoffrois L; Kerbrat P; Bui V; Flechon A
    Ann Oncol; 2008 Aug; 19(8):1465-1469. PubMed ID: 18385203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
    Einhorn LH; Brames MJ; Juliar B; Williams SD
    J Clin Oncol; 2007 Feb; 25(5):513-6. PubMed ID: 17290059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor.
    De Giorgi U; Rosti G; Aieta M; Testore F; Burattini L; Fornarini G; Naglieri E; Lo Re G; Zumaglini F; Marangolo M
    Eur Urol; 2006 Nov; 50(5):1032-8; discussion 1038-9. PubMed ID: 16757095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.
    Nicolai N; Necchi A; Gianni L; Piva L; Biasoni D; Torelli T; Stagni S; Milani A; Pizzocaro G; Salvioni R
    BJU Int; 2009 Aug; 104(3):340-6. PubMed ID: 19239440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
    Farmakis D; Pectasides M; Pectasides D
    Eur Urol; 2005 Sep; 48(3):400-7. PubMed ID: 15964136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
    Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J
    BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors.
    Shiraishi T; Nakamura T; Mikami K; Takaha N; Kawauchi A; Miki T
    Int J Clin Oncol; 2009 Oct; 14(5):436-41. PubMed ID: 19856053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer.
    McKenzie HS; Mead G; Huddart R; White JD; Rustin GJS; Hennig IM; Cozens K; Cross N; Bowers M; Wheater MJ
    Clin Genitourin Cancer; 2018 Dec; 16(6):458-465.e2. PubMed ID: 30115544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
    Mulherin BP; Brames MJ; Einhorn LH
    Am J Clin Oncol; 2015 Aug; 38(4):373-6. PubMed ID: 26214082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
    Necchi A; Nicolai N; Mariani L; Lo Vullo S; Giannatempo P; Raggi D; Farè E; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Milani A; Gianni AM; Salvioni R
    Clin Genitourin Cancer; 2014 Feb; 12(1):63-69.e1. PubMed ID: 24161525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer].
    Nomoto T; Mizutani Y; Mikami K; Nakamura T; Nakanishi H; Kawauchi A; Miki T
    Nihon Hinyokika Gakkai Zasshi; 2006 May; 97(4):630-5. PubMed ID: 16768143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.